Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-FR Version v11-EN
Language French English
Date Updated 2023-07-07 2023-06-29
Drug Identification Number 02468247 02468247
Brand name APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR
Common or Proper name EMTRICITABINE/TENOFOVIR/EFAVIRENZ EMTRICITABINE/TENOFOVIR/EFAVIRENZ
Company Name APOTEX INC APOTEX INC
Ingredients TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ
Strength(s) 300MG 200MG 600MG 300MG 200MG 600MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 30 BTL 30 BTL
ATC code J05AR J05AR
ATC description DIRECT ACTING ANTIVIRALS DIRECT ACTING ANTIVIRALS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-04-11 2023-04-11
Estimated end date 2023-07-07 2023-07-07
Actual end date 2023-07-04
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments
Health Canada comments